Company intelligence / Profile preview
Polpharma Biologics Group
Amsterdam, Netherlands
- Ownership
- Private
- Employees
- ~300
- Development stage
- Other
01
Overview
Two biosimilars (ranibizumab, natalizumab) commercialized/approved via partnerships. Ranibizumab biosimilar (FYB201) submitted for BLA in the US, and partnered for US and EU/Canada commercialization. Multiple programs in late-stage or commercial phase; PK/PD comparability established for investigational vedolizumab biosimilar vs. reference in IBD[2][5][15].
- Therapeutic areas
- GastroenterologyNeurologyOphthalmology
- Modalities
- Monoclonal antibodyMonoclonal antibody fragmentBiologicRecombinant protein
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
FormyconBioeqCoherusTevaSandozProBioGenChime Biologics
Beyond the preview
Go deeper on Polpharma Biologics Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Polpharma Biologics Group.